Unknown NA INTERVENTIONAL 3-arm NCT05204784

Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis (RHEACT)

A Randomized Controlled Prospective Single-center Feasibility Study of Rheopheresis for Raynaud's Syndrome and Digital Ulcers in Systemic Sclerosis

Sponsor: DiaMed GmbH

Conditions Digital Ulcer Raynaud Phenomenon Scleroderma Systemic Sclerosis

Interventions Intravenous Infusion Rheopheresis treatment

Updated 4 times since 2022 Last updated: Mar 18, 2022 Started: Feb 28, 2022 Primary completion: Dec 31, 2023 Completion: Jun 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Digital Ulcer and Raynaud Phenomenon and is currently ongoing. DiaMed GmbH leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Recruiting → Unknown
Apr 2022 — Jul 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Feb 2022 — Apr 2022 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

DiaMed GmbH
Peter Korsten

Data source: University of Göttingen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Göttingen, Germany